Featured Research

from universities, journals, and other organizations

Potential treatment for Chikungunya discovered

Date:
February 28, 2011
Source:
Agency for Science, Technology and Research (A*STAR), Singapore
Summary:
Researchers have discovered two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.

The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS (NYSE Euronext: VLS), a French biopharmaceutical company, has announced the discovery of two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.

The international team of scientists, coordinated by Dr Lucile Warter of SIgN, has published their groundbreaking discovery in the Journal of Immunology.

Chikungunya is prevalent in Africa, South Asia, and South-East Asia and is transmitted by the Aedes mosquito, the same mosquito that spreads dengue fever. In Singapore alone, over 1000 Chikungunya cases were reported over the period 2008-2010. Dr Warter and her collaborators used Humalex, a VIVALIS technology platform designed to identify and generate fully human monoclonal antibodies, to develop two antibodies that could neutralize several Chikungunya strains in vitro by culturing immune cells from an individual who had developed resistance to Chikungunya. Monoclonal antibodies can be more potent and have fewer side effects than conventional small molecule drugs.

"The discovery of these antibodies is a big step forward in combating a disease that presently has no available vaccine or specific treatment. The use of VIVALIS' Humalex was invaluable in helping us isolate the target antibodies from the cultured immune cells. We hope to further validate the use of these antibodies as a viable treatment for Chikungunya." said Dr Warter. She added that further testing in vivo would have to be carried out to validate the antibodies' performance as a potential treatment for Chikungunya.

"It is thanks to the successful synergy between industry and SIgN that the development of two antibodies against a disease that is on the rise has been accomplished. The combination of Humalexฎ technology, SIgN's expertise in human immunology, virology and molecular biology, and Singapore's location as a hub for Asia helped to speed up the selection, sequencing and characterization of the most potent antibody candidates. I am delighted to note that this breakthrough was achieved in less than a year from the start of the project," said SIgN Chairman Prof Philippe Kourilsky.

"The new platform used by SIgN for the generation of fully human monoclonal antibody is already providing excellent results, and we hope to generate a number of new fully human monoclonal antibodies that could be used as therapeutics," said SIgN Scientific Director Prof. Paola Castagnoli.

"The discovery of these new fully human monoclonal antibodies with strong neutralizing activities against the Chikungunya virus constitutes an an additional testimony of the efficiency of the Humalex platform. Coming shortly after the signature of a major commercial agreement with sanofi Pasteur, the vaccine division of Sanofi Aventis, this discovery is a further validation of the power of VIVALIS Humalex antibody discovery platform. It is a first milestone in our research partnership with SIgN and we expect to benefit from the excellent scientific input from SIgN scientists in the field of immunology in future collaborative programs," commented Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS.


Story Source:

The above story is based on materials provided by Agency for Science, Technology and Research (A*STAR), Singapore. Note: Materials may be edited for content and length.


Journal Reference:

  1. L. Warter, C. Y. Lee, R. Thiagarajan, M. Grandadam, S. Lebecque, R. T. P. Lin, S. Bertin-Maghit, L. F. P. Ng, J.-P. Abastado, P. Despres, C.-I. Wang, A. Nardin. Chikungunya Virus Envelope-Specific Human Monoclonal Antibodies with Broad Neutralization Potency. The Journal of Immunology, 2011; 186 (5): 3258 DOI: 10.4049/jimmunol.1003139

Cite This Page:

Agency for Science, Technology and Research (A*STAR), Singapore. "Potential treatment for Chikungunya discovered." ScienceDaily. ScienceDaily, 28 February 2011. <www.sciencedaily.com/releases/2011/02/110216111935.htm>.
Agency for Science, Technology and Research (A*STAR), Singapore. (2011, February 28). Potential treatment for Chikungunya discovered. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2011/02/110216111935.htm
Agency for Science, Technology and Research (A*STAR), Singapore. "Potential treatment for Chikungunya discovered." ScienceDaily. www.sciencedaily.com/releases/2011/02/110216111935.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) — The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) — Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) — A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) — The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins